Redeye comments on Mendus presenting ADVANCE II survival data at ASH 2022. The study had not yet reached median relapse-free survival after a median c19.4 months follow-up, indicating considerably better mRFS than historical QUAZAR AML-001 controls. We increase our estimated likelihood of approval for DCP-001 and valuation.